专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2005081980A3 METHODS AND COMPOSITIONS RELATING TO CHITINASES AND CHITINASE-LIKE MOLECULES AND MODULATION OF OSTEOCLASTS 审中-公开
标题翻译：方法和组合物相对于CHITINASES和CHITINASE-LIKE分子和调节OSTEOCLASTS
公开(公告)号：WO2005081980A3
公开(公告)日：2006-04-27
申请号：PCT/US2005005768
申请日：2005-02-24
申请人： MEDIMMUNE INC , MAO SU-YAU , WHITE WENDY
发明人： MAO SU-YAU , WHITE WENDY
IPC分类号： A61K39/40 , A61K39/395 , A61K39/42 , C07K16/00 , C07K16/40 , C12P21/08
CPC分类号： C07K16/40 , A61K2039/505 , C07K2317/76
摘要： The invention relates to the novel discovery that inhibiting a C/CLP modulates (e.g., inhibits) inflammation, as well as, bone and tissue destruction in arthritis. The present invention relates to compositions and methods for the treatment of bone metabolism and connective tissue disorders and diseases (e.g., bone metabolism disorders, osteoarthritis, psoriatic arthritis, rheumatoid arthritis, and osteoporosis) by modulating (e.g., inhibiting) at least one C/CLP. In particular where the inhibition of at least one C/CLP results in the inhibition of osteoclast activity, including but not limited to, osteoclast maturation, osteoclast differentiation, osteoclast proliferation, and osteoclastogenesis. One particular embodiment of the invention relates to inhibiting the expression or activity of one or more C/CLPs.
摘要翻译：本发明涉及抑制C / CLP调节（例如抑制）炎症以及关节炎中骨和组织破坏的新发现。本发明涉及通过调节（例如，抑制）至少一种C / C作用来治疗骨代谢和结缔组织疾病和疾病（例如骨代谢障碍，骨关节炎，银屑病关节炎，类风湿性关节炎和骨质疏松症）的组合物和方法， CLP。特别是至少一种C / CLP的抑制导致破骨细胞活性的抑制，包括但不限于破骨细胞成熟，破骨细胞分化，破骨细胞增殖和破骨细胞发生。本发明的一个具体实施方案涉及抑制一种或多种C / CLP的表达或活性。

12. 发明申请

WO2005117967A2 ANTI-IL-9 ANTIBODY FORMULATIONS AND USES THEREOF 审中-公开
标题翻译：抗IL-9抗体制剂及其用途
公开(公告)号：WO2005117967A2
公开(公告)日：2005-12-15
申请号：PCT/US2005/012464
申请日：2005-04-12
申请人： MEDIMMUNE, INC. , ALLAN, Christian, B.
发明人： ALLAN, Christian, B.
IPC分类号： A61K39/395
CPC分类号： A61K39/39591 , A61K47/02 , A61K47/183 , A61K2039/505 , C07K16/065 , C07K16/244
摘要： The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to an IL-9 polypeptide, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to an IL-9 polypeptide, which formulations are substantially free of surfactants, sugars, sugar alcohols, amino acids other than histidine (preferably with pKa values of less than 5 and above 7), and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating a disease or disorder associated with or characterized by aberrant expression and/or activity of an IL-9 polypeptide, a disease or disorder associated with or characterized by aberrant expression and/or activity of the IL-9R or one or more subunits thereof, an autoimmune disease, an inflammatory disease, a proliferative disease, or an infection (preferably, a respiratory infection), or one or more symptoms thereof, utilizing the liquid formulations of the present invention.
摘要翻译：本发明提供免疫特异性结合IL-9多肽的抗体或抗体片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且抗体或抗体片段的生物活性几乎不损失或不损失，即使在长时间的存储。特别地，本发明提供免疫特异性结合IL-9多肽的抗体或其片段的液体制剂，该制剂基本上不含表面活性剂，糖，糖醇，组氨酸以外的氨基酸（优选pKa值小于 5和7以上），和/或其它常用赋形剂。此外，本发明提供了预防，治疗或改善与IL-9多肽的异常表达和/或活性相关或特征性的疾病或病症的方法，所述异常表达和/或活性与利用本发明的液体制剂，其IL-9R或其一个或多个亚单位，自身免疫性疾病，炎性疾病，增殖性疾病或感染（优选呼吸道感染）或其一种或多种症状。

13. 发明申请

WO2005035576A3 METHOD OF RESISTING OSTEOCLAST FORMATION 审中-公开
标题翻译：电磁波形成的方法
公开(公告)号：WO2005035576A3
公开(公告)日：2005-12-15
申请号：PCT/US2004027796
申请日：2004-08-27
申请人： MEDIMMUNE INC , UNIV PITTSBURGH , WHITE WENDY , ROODMAN G DAVID , CHOI SUN JIN , OBA YASUO
发明人： WHITE WENDY , ROODMAN G DAVID , CHOI SUN JIN , OBA YASUO
IPC分类号： C07K14/52 , C07K16/24 , C12N5/078
CPC分类号： C07K14/52 , C07K16/24 , C12N5/0643 , C12N2500/38 , C12N2501/185 , C12N2501/21
摘要： A method of inhibiting osteoclast formation including inhibiting eosinophil chemotactic factor-L expression or activity. This may be accomplished by a number of means, including the use of anti-ECF-L antibody, antisense S-oligonucleotide to ECF-L, mECF-L polyclonal antisera, rabbit preimmune antisera, OPG RANK-Fc and combinations thereof, as well as other inhibiting materials. In another embodiment, osteoclast formation is inhibited by inhibiting RANKL formation. In a further embodiment, a method of inhibiting osteoclast formation is accomplished by means of mECF-L in the presence of RANKL.
摘要翻译：一种抑制破骨细胞形成的方法，包括抑制嗜酸性粒细胞趋化因子-L表达或活性。这可以通过许多方法来实现，包括使用抗ECF-L抗体，ECF-L的反义S-寡核苷酸，mECF-L多克隆抗血清，兔免疫前抗血清，OPG RANK-Fc及其组合作为其他抑制材料。在另一个实施方案中，通过抑制RANKL形成来抑制破骨细胞的形成。在另一个实施方案中，通过在RANKL存在下的mECF-L来实现抑制破骨细胞形成的方法。

14. 发明申请

WO2004091375A3 EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL DISORDERS 审中-公开
标题翻译： EPHA2和非神经性高增殖性细胞病变
公开(公告)号：WO2004091375A3
公开(公告)日：2005-07-14
申请号：PCT/US2004011482
申请日：2004-04-12
申请人： MEDIMMUNE INC , KIENER PETER A , KINCH MICHAEL S , LANGERMANN SOLOMON , REED JENNIFER L
发明人： KIENER PETER A , KINCH MICHAEL S , LANGERMANN SOLOMON , REED JENNIFER L
IPC分类号： A61B20060101 , A61K39/00 , A61K39/395 , A61K49/00 , C07K16/28 , C07K16/32
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/32
摘要： The present invention relates to methods and compositions designed for the treatment, management, or prevention of a non-neoplastic hyperproliferative cell or excessive cell accumulation disorders, particularly those involving hyperproliferation of epithelial or endothelial cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and increase EphA2 cytoplasmic tail phosphorylation and/or increase EphA2 autophosphorylation. in cells which EphA2 has been agonized. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and reduce EphA2 activity (other than autophosphorylation). In another embodiment, the methods of the invention comprise administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and decrease a pathology-causing cell phenotype (e.g., a pathology-causing epithelial cell phenotype or a pathology-causing endothelial cell phenotype). In another embodiment, the methods of the invention comprise the administration of an effective amount. of one or more EphA2 agonistic agents that are EphA2 antibodies that bind to EphA2 with a very low Koff rate. In prefer-red embodiments, agents of the invention are inonoclonal antibodies. The invention also provides pharmaceutical compositions comprising one or more EphA2 agonistic agents of the invention either alone or in combination with one or more other agents useful in therapy for non-neoplastic hyperproliferative cell or excessive cell accumulation disorders.
摘要翻译：本发明涉及设计用于治疗，管理或预防非肿瘤性过度增殖性细胞或过度细胞累积障碍，特别是涉及上皮细胞或内皮细胞过度增殖的方法和组合物。在一个实施方案中，本发明的方法包括施用有效量的一种或多种结合EphA2并增加EphA2细胞质尾磷酸化和/或增加EphA2自磷酸化的EphA2激动剂。在EphA2被激活的细胞中。在另一个实施方案中，本发明的方法包括施用有效量的一种或多种EphA2激动剂，其结合EphA2并降低EphA2活性（除了自磷酸化）。在另一个实施方案中，本发明的方法包括施用有效量的一种或多种结合EphA2的EphA2激动剂并减少病理学引起的细胞表型（例如，导致病理的上皮细胞表型或致病性病因的内皮细胞表型）。在另一个实施方案中，本发明的方法包括施用有效量。的一种或多种EphA2激动剂，其是以非常低的Koff率与EphA2结合的EphA2抗体。在优选的实施方案中，本发明的试剂是异源抗体。本发明还提供包含本发明的一种或多种EphA2激动剂的药物组合物，其单独或与一种或多种其它可用于治疗非肿瘤性过度增殖性细胞或过度细胞累积障碍的其它药物组合。

15. 发明申请

WO2005055948A2 EPHA2, EPHA4 AND LMW-PTP AND METHODS OF TREATMENT OF HYPERPROLIFERATIVE CELL DISORDERS 审中-公开
标题翻译： EPHA2，EPHA4和LMW-PTP及治疗高增殖性细胞病的方法
公开(公告)号：WO2005055948A2
公开(公告)日：2005-06-23
申请号：PCT/US2004/041023
申请日：2004-12-06
申请人： MEDIMMUNE, INC. , KINCH, Michael, S.
发明人： KINCH, Michael, S.
IPC分类号： A61K
CPC分类号： A61K38/1709 , A61K9/127 , A61K48/00 , A61K2039/505 , C07K16/2866 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C12N9/12 , C12N9/16 , C12Y301/03048
摘要： The present invention relates to methods and compositions designed for treatment, management, or prevention of a hyperproliferative cell disease, particular cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing low molecular weight protein tyrosine kinase ("LMW-PTP") in particular using moieties that bind an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, and inhibits or reduces LMW-PTP expression and/or activity. In i one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more agents that inhibit LMW-PTP expression and/or activity operatively associated with the delivery vehicle. In another embodiment, the method of the invention comprises administering to a subject a composition comprising a nucleic acid comprising a nucleotide sequence encoding an EphA2 or EphA4 targeting moiety and an agent that inhibits or reduces LMW-PTP expression and/or activity. In yet another embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety and a nucleic acid comprising a nucleotide sequence encoding an agent that inhibits or reduces LMW-PTP expression and/or activity, where the nucleic acid is operatively associated with the delivery vehicle. Pharmaceutical compositions are also provided by the present invention.
摘要翻译：本发明涉及用于治疗，治疗或预防过度增殖性细胞疾病，特定癌症的方法和组合物。本发明的方法包括施用有效量的靶向表达低分子量蛋白酪氨酸激酶（“LMW-PTP”）的细胞的组合物，特别是使用结合Eph家族受体酪氨酸激酶（例如EphA2或EphA4）的部分，并且抑制或降低LMW-PTP表达和/或活性。在一个实施方案中，本发明的方法包括向受试者施用包含与递送载体连接的EphA2或EphA4靶向部分的组合物，以及一种或多种抑制LMW-PTP表达和/或与递送有效相关的活性的试剂车辆。在另一个实施方案中，本发明的方法包括向受试者施用包含核酸的组合物，所述核酸包含编码EphA2或EphA4靶向部分的核苷酸序列和抑制或降低LMW-PTP表达和/或活性的试剂。在另一个实施方案中，本发明的方法包括对受试者施用包含EphA2或EphA4靶向部分的组合物和包含编码抑制或降低LMW-PTP表达和/或活性的试剂的核苷酸序列的核酸，其中核酸与递送载体可操作地相关联。药物组合物也由本发明提供。

16. 发明申请

WO2004066957A3 ANTI-INTEGRIN alphanubeta3 ANTIBODY FORMULATIONS AND USES THEREOF 审中-公开
标题翻译：抗生素alphanubeta3抗体制剂及其用途
公开(公告)号：WO2004066957A3
公开(公告)日：2005-04-07
申请号：PCT/US2004002701
申请日：2004-01-30
申请人： MEDIMMUNE INC , ALLAN CHRISTIAN B
发明人： ALLAN CHRISTIAN B
IPC分类号： A61K20060101 , A61K39/395 , C07K16/28
CPC分类号： A61K39/39591 , C07K16/2848
摘要： The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin alphanubeta3 , which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin alphanubeta3 , which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin alphanubeta3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.
摘要翻译：本发明提供了抗体或抗体片段的液体制剂，其免疫特异性结合整联蛋白alphanubeta3，该制剂表现出稳定性，低至不可检测的聚集水平，以及甚至在长时间内抗体或抗体片段的生物活性也很少甚至没有丧失储存期特别地，本发明提供免疫特异性结合整联蛋白氨基酸3的抗体或其片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常用赋形剂。此外，本发明提供了预防，治疗或改善炎性病症，自身免疫性疾病，与整合素alphanubeta3的异常表达和/或活性相关的病症，与异常骨代谢相关的疾病，与异常血管生成或癌症相关的病症的方法利用本发明的液体制剂。

17. 发明申请

WO2003105894A1 STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS 审中-公开
标题翻译：稳定液体抗RSV抗体制剂
公开(公告)号：WO2003105894A1
公开(公告)日：2003-12-24
申请号：PCT/US2003/018913
申请日：2003-06-16
申请人： MEDIMMUNE, INC. , OLIVER, Cynthia, N. , SHANE, Erica , ISSAACS, Benjamin, S. , ALLAN, Christian, B. , CHANG, Stephen
发明人： OLIVER, Cynthia, N. , SHANE, Erica , ISSAACS, Benjamin, S. , ALLAN, Christian, B. , CHANG, Stephen
IPC分类号： A61K39/385
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS ® or an antigenbinding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS ® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS ® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译：本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗体结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且很少甚至没有损失即使在长时间的储存期间，它们的生物活性也可以是其抗原结合片段。特别地，本发明提供了免疫特异性结合RSV抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。

18. 发明申请

WO02060919A3 MOLECULES WITH EXTENDED HALF-LIVES, COMPOSITIONS AND USES THEREOF 审中-公开
标题翻译：具有扩展的半衰期，组合物和其用途的分子
公开(公告)号：WO02060919A3
公开(公告)日：2003-09-04
申请号：PCT/US0148432
申请日：2001-12-12
申请人： MEDIMMUNE INC , DALL ACQUA WILLIAM , JOHNSON LESLIE S , WARD ELIZABETH SALLY
发明人： DALL ACQUA WILLIAM , JOHNSON LESLIE S , WARD ELIZABETH SALLY
IPC分类号： G01N33/534 , A61K38/00 , A61K39/00 , A61K39/395 , A61K47/48 , A61K49/00 , A61P31/16 , A61P37/00 , C07K14/705 , C07K16/00 , C07K16/08 , C07K16/18 , C07K16/46 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C07H21/04 , A61K48/00
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/48507 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
摘要翻译：本发明提供了由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的IgG，非IgG免疫球蛋白，蛋白质和非蛋白质试剂的分子，其具有一个或更多的氨基酸修饰，其增加FcRn的恒定结构域或片段的亲和力。具有增加的半衰期的这种蛋白质和分子具有在这种分子的治疗，预防或诊断使用中需要较少量和/或更少频繁给药的优点。

19. 发明申请

WO02060919A9 MOLECULES WITH EXTENDED HALF-LIVES, COMPOSITIONS AND USES THEREOF 审中-公开
标题翻译：具有延长半衰期的分子，组合物及其用途
公开(公告)号：WO02060919A9
公开(公告)日：2003-01-03
申请号：PCT/US0148432
申请日：2001-12-12
申请人： MEDIMMUNE INC , DALL ACQUA WILLIAM , JOHNSON LESLIE S , WARD ELIZABETH SALLY
发明人： DALL ACQUA WILLIAM , JOHNSON LESLIE S , WARD ELIZABETH SALLY
IPC分类号： G01N33/534 , A61K38/00 , A61K39/00 , A61K39/395 , A61K47/48 , A61K49/00 , A61P31/16 , A61P37/00 , C07K14/705 , C07K16/00 , C07K16/08 , C07K16/18 , C07K16/46 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C07K
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/48507 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
摘要翻译：本发明提供由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的分子，包括IgG，非IgG免疫球蛋白，蛋白质和非蛋白质剂，所述分子具有一个或更多增加恒定结构域或片段对FcRn的亲和力的氨基酸修饰。具有增加的半衰期的此类蛋白质和分子具有在治疗，预防或诊断使用此类分子时需要更少量和/或更少频率给药的优点。

20. 发明申请

WO2002059156A2 THERAPEUTIC COMPOUNDS STRUCTURALLY-LINKED TO BACTERIAL POLYPEPTIDES 审中-公开
标题翻译：结构化结合到细菌多糖的治疗化合物
公开(公告)号：WO2002059156A2
公开(公告)日：2002-08-01
申请号：PCT/US2001/051037
申请日：2001-12-20
申请人： MEDIMMUNE, INC. , WASHINGTON UNIVERSITY
发明人： HULTGREN, Scott, J. , LANGERMANN, Solomon , SAUER, Frederic, G.
IPC分类号： C07K19/00
CPC分类号： C07K14/245 , A61K39/00 , C07K2319/00
摘要： A protein construct comprising a pilus protein portion, preferably a structurally stabilized pilus-protein, and an additional, or effector, portion other than a pilus protein or chaperone and wherein said effector portion serves to stabilize the pilus protein portion and to confer a therapeutic activity, such as vaccine activity or anti-microbial or anticancer activity, on the protein construct is disclosed. Such effector portion commonly comprises a donor strand complementary segment capable of structurally stabilizing a pilus protein subunit and attaching the auxiliary portion to said subunit to form the pilus protein analog of the invention. Methods of using said protein constructs are also disclosed as well as the formation and use of analogs comprising fragments of a pilus protein linked to effector components to produce immunogenic and/or therapeutic activity.
摘要翻译：一种蛋白质构建体，其包含真菌蛋白质部分，优选结构稳定的菌毛蛋白，以及除了毛壳蛋白或伴侣之外的另外的或效应子部分，并且其中所述效应部分用于稳定菌毛蛋白质部分并赋予治疗活性，例如疫苗活性或抗微生物活性或抗癌活性。这种效应部分通常包含能够结构稳定菌毛蛋白亚基并将辅助部分附着到所述亚单位以形成本发明的菌毛蛋白类似物的供体链互补区段。还公开了使用所述蛋白质构建体的方法，以及包含与效应子组分连接的真菌蛋白片段的类似物的形成和用途，以产生免疫原性和/或治疗活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式